Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.

MLA

Pulczynski, Elisa Jacobsen, et al. “Elderly Long-Term Survivors in the Nordic Phase II Study with First-Line Maintenance Temozolomide for Primary Central Nervous System Lymphoma: A 10-Year Follow-Up.” Haematologica, vol. 109, no. 7, July 2024, pp. 2359–63. EBSCOhost, https://doi.org/10.3324/haematol.2024.285207.

APA

Pulczynski, E. J., Simonsen, M. R., Kuittinen, O., Fagerli, U.-M., Erlanson, M., Fluge, Ø., Leppä, S., Østenstad, B., Fosså, A., Eriksson, M., El-Galaly, T., Kuitunen, H., Papworth, K., Ljungqvist, M., Pedersen, M. B., & Pollari, M. (2024). Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up. Haematologica, 109(7), 2359–2363. https://doi.org/10.3324/haematol.2024.285207

Chicago

Pulczynski, Elisa Jacobsen, Mikkel Runason Simonsen, Outi Kuittinen, Unn-Merete Fagerli, Martin Erlanson, Øystein Fluge, Sirpa Leppä, et al. 2024. “Elderly Long-Term Survivors in the Nordic Phase II Study with First-Line Maintenance Temozolomide for Primary Central Nervous System Lymphoma: A 10-Year Follow-Up.” Haematologica 109 (7): 2359–63. doi:10.3324/haematol.2024.285207.